Compositions for treatment of disorders ameliorated by muscarinic receptor activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotics for treating schizophrenia have limited efficacy and severe side effects, and muscarinic agonists face challenges due to side effects from binding to non-target receptor subtypes, hindering their clinical use.
Innovation Solution
A medicament comprising a muscarinic activator, such as xanomeline, combined with a muscarinic inhibitor, like trospium chloride, to achieve therapeutic effects while minimizing side effects through a proprietary algorithm determining a 'Theta score' above 230.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If muscarinic agonists are used to treat schizophrenia, then therapeutic effects are achieved, but unwanted side effects occur due to binding to non-target muscarinic receptor subtypes
Solution Approach 1:
The patent applies segmentation by dividing the muscarinic receptor system into specific subtypes (M1, M2, M3, M4, M5) and designing agonists that selectively target only M1 and M4 subtypes. This selective activation segments the therapeutic action from the harmful side effects caused by non-specific binding to other muscarinic subtypes, thereby improving reliability while reducing harmful effects.
Solution Approach 2:
The patent employs local quality by creating muscarinic agonists with differentiated binding properties for different receptor subtypes. The agonists are designed to have high affinity and selectivity for M1 and M4 receptors specifically, while having minimal affinity for M2, M3, and M5 subtypes. This localized specificity ensures therapeutic effects are achieved through M1/M4 activation without the side effects associated with broader muscarinic receptor binding.
2Reliability
If current antipsychotics are used to treat schizophrenia, then some therapeutic effect is achieved, but severe side effects and limited efficacy persist
Solution Approach 1:
The patent applies parameter changes by fundamentally shifting from dopamine receptor antagonism (current antipsychotic mechanism) to muscarinic receptor agonism with M1/M4 selectivity. This parameter change in the pharmacological mechanism enables achievement of therapeutic effects through a different neural pathway, potentially overcoming the side effect limitations and efficacy constraints of existing antipsychotics.
Data Source
AI summary
Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.